Tildacerfont is under clinical development by Spruce Biosciences and currently in Phase II for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). According to GlobalData, Phase II drugs for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Tildacerfont LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tildacerfont overview
Tildacerfont (SPR-001) is under development for the treatment of classic congenital adrenal hyperplasia and polycystic ovary syndrome. The drug candidate is a small molecule formulated as a capsule and tablet, administered through oral route. It acts by targeting corticotropin-releasing factor receptor-1. It was under development for the treatment of cushing's disease.
Spruce Biosciences overview
Spruce Biosciences is a biopharmaceutical company that develops and commercializes drugs, novel therapies for the rare endocrine disorders with significant unmet medical need. It’s product pipeline include Tildacerfont, a CRF1 receptor antagonist to treat adult and pediatric classic congenital adrenal hyperplasia and polycystic ovary syndrome. The company focuses on reducing the hyperresponsiveness of adrenocorticotropic hormone (ACTH), a hormone involved in the production of cortisol and improve disease control and glucocorticoid steroid burden. The company offers services such as medical services, healthcare services, clinical trials among others. Spruce Biosciences is headquartered in South San Francisco, California, the US.
For a complete picture of Tildacerfont’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
